<DOC>
	<DOCNO>NCT00522990</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose AT9283 give patient ALL , AML , CML , high-risk myelodysplastic syndrome , myelofibrosis myeloid metaplasia . Researchers want perform pharmacokinetic ( PK ) test blood find quickly study drug leave body body breaks drug . The safety effectiveness drug also study .</brief_summary>
	<brief_title>Study Assess Safety Escalating Doses AT9283 , Patients With Leukemias</brief_title>
	<detailed_description>Dose escalation study AT9283 administer patient refractory hematological malignancy . Study objectives include identification MTD dose limit toxicity , preliminary assessment efficacy definition pharmacokinetic profile</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Provision sign write informed consent 2 . Histological cytological confirmation one following : Relapsed refractory AML ALL ; acute leukaemia patient unsuitable refuse standard therapy CML chronic phase , accelerate phase blast crisis resistant refractory standard therapy Highrisk MDS , define presence : ) Refractory anemia excess blast ( RAEB , 519 % bone marrow blast ) ii ) RAEB transformation AML ( RAEBT 2030 % bone marrow blast ) Advanced MMM define presence one follow feature : ) Hemoglobin &lt; 10 gm/dL ( 100 g/L ) ii ) Platelet count &lt; 100 x 109/L iii ) White blood cell count &lt; 4 x 109/L iv ) Symptomatic splenomegaly diseaserelated symptom inadequately control conventional therapy 3 . ECOG performance status 0 , 1 2 4 . Male female , age 18 year old 5 . Negative pregnancy test history surgical sterility evidence postmenopausal status ( postmenopausal status define follow : natural menopause menses &gt; 1 year ago ; radiation induce oophorectomy last menses &gt; 1 year ago ; chemotherapy induce menopause 1 year interval since last menses 1 . Inadequate liver function demonstrate serum bilirubin ≥1.5 time upper limit reference range ( ULRR ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) alkaline phosphatase ( ALP ) ≥2.5 time ULRR ( ≥5 time ULRR presence liver metastasis ) 2 . Impaired renal function demonstrate either isolated creatinine value ≥1.5 time ULRR OR creatinine clearance &lt; 50 mL/min determine CockcroftGault formula . Note requirement determine formal creatinine clearance patient 's serum creatinine value ≥1.5 time ULRR . 3 . Radiotherapy chemotherapy within 14 day prior first dose AT9283 administer ( Day 1 , dose level 1 ) . Planned use hydroxyurea permit described section 11.9 . 4 . Receiving investigational anticancer treatment concurrently within 14 day prior start AT9283 infusion ( Day 1 ) 5 . Unresolved CTCAE grade 2 great toxicity ( stable toxicity ) previous anticancer therapy exclude alopecia 6 . Any evidence severe uncontrolled systemic condition ( e.g. , severe hepatic impairment ) current unstable uncompensated respiratory cardiac condition make undesirable patient participate study could jeopardize compliance protocol 7 . Active , uncontrolled central nervous system disease 8 . Ischemic heart disease myocardial infarction unstable cardiac disease within 3 month study entry 9 . Prior infection human immunodeficiency virus ( HIV ) , hepatitis B C viruses screen viral infection require entry study 10 . Major surgery within 28 day prior start AT9283 infusion ( Day 1 ) exclude skin biopsy procedures insertion central venous access device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>